Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Branded versus generic clozapine: bioavailability comparison and interchangeability issues.

Y W Lam1, L Ereshefsky, G B Toney

  • 1Department of Pharmacology, University of Texas Health Science Center at San Antonio, 78229-3900, USA. lamf@uthscsa.edu

The Journal of Clinical Psychiatry
|April 18, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mapping of validated apathy scales onto the apathy diagnostic criteria for neurocognitive disorders.

International psychogeriatrics·2025
Same author

A new class of antimicrobial therapeutics targeting the envelope stress response of Gram-negative bacteria: abridged secondary publication.

Hong Kong medical journal = Xianggang yi xue za zhi·2023
Same author

Validation of a suite of ERP and QEEG biomarkers in a pre-competitive, industry-led study in subjects with schizophrenia and healthy volunteers.

Schizophrenia research·2023
Same author

A Framework for Developing Pharmacotherapy for Agitation in Alzheimer's Disease: Recommendations of the ISCTM* Working Group.

The journal of prevention of Alzheimer's disease·2020
Same author

Exploration of the bovine colostrum proteome and effects of heat treatment time on colostrum protein profile.

Journal of dairy science·2017
Same author

A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients.

Molecular psychiatry·2016

Generic clozapine, used for refractory schizophrenia, showed significant pharmacokinetic differences in nearly 40% of patients compared to the branded version. Individual patient assessment is crucial when considering formulation changes.

Area of Science:

  • Pharmacology
  • Psychiatry
  • Pharmaceutical Sciences

Background:

  • Clozapine is the gold standard treatment for refractory schizophrenia.
  • Generic clozapine formulations are now available, but concerns exist regarding their bioequivalence and clinical interchangeability.
  • Regulatory waivers have allowed generic clozapine market entry without standard bioequivalence trials.

Observation:

  • A prospective, randomized, crossover study compared generic clozapine (Zenith Goldline) with branded Clozaril (Novartis) in schizophrenia patients.
  • Steady-state pharmacokinetics, pharmacodynamics, and tolerability were evaluated.
  • Preliminary bioavailability results are presented.

Findings:

  • While mean plasma concentration-time curves were comparable, significant intraindividual pharmacokinetic differences were observed in almost 40% of patients between the two clozapine formulations.

Related Experiment Videos

  • These findings challenge the concept of average bioequivalence for individual patient care.
  • Differences in key pharmacokinetic parameters were noted.

    • Implications:

    • The study highlights the potential risks of generic clozapine substitution due to individual pharmacokinetic variability.
    • Average bioequivalence may not guarantee therapeutic interchangeability for all patients.
    • Clinical decisions to switch formulations must be individualized, prioritizing patient outcomes and close monitoring.